SYSTIMMUNE INC.

15318 NE 95TH St, Redmond, Washington, United States

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

88.9%

Phase 3

11.1%

Trial Status Distribution

Active, not recruiting

22.2%

Recruiting

77.8%

Clinical Trials

Trials sponsored by this organization (9)

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

Phase 3

Recruiting

interventional

Aug 2026550 participants

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Phase 1

Active, not recruiting

interventional

Jul 2025160 participants

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Phase 1

Recruiting

interventional

Apr 2025120 participants

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

interventional

Apr 2025120 participants

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

Phase 1

Recruiting

interventional

Dec 2024120 participants

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Phase 1

Recruiting

interventional

Feb 2024280 participants

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer

Phase 1

Recruiting

interventional

Jan 2024144 participants

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Phase 1

Recruiting

interventional

Aug 2023470 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations